TISIDB

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Mitochondrion matrix Nucleus Note=Mainly localizes in the mitochondrion. A small fraction localizes to the nucleus, where the 2-oxoglutarate dehydrogenase complex is required for histone succinylation.
Domain	PF00198 2-oxoacid dehydrogenases acyltransferase (catalytic domain) PF00364 Biotin-requiring enzyme
Function	Dihydrolipoamide succinyltransferase (E2) component of the 2-oxoglutarate dehydrogenase complex (By similarity). The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO(2) (By similarity). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711). A fraction of the 2-oxoglutarate dehydrogenase complex also localizes in the nucleus and is required for lysine succinylation of histones: associates with KAT2A on chromatin and provides succinyl-CoA to histone succinyltransferase KAT2A (PubMed:29211711).

> Gene Ontology [ TOP ]
Biological Process	GO:0006084 acetyl-CoA metabolic process GO:0006091 generation of precursor metabolites and energy GO:0006099 tricarboxylic acid cycle GO:0006520 cellular amino acid metabolic process GO:0006553 lysine metabolic process GO:0006554 lysine catabolic process GO:0006637 acyl-CoA metabolic process GO:0006732 coenzyme metabolic process GO:0006790 sulfur compound metabolic process GO:0009060 aerobic respiration GO:0009063 cellular amino acid catabolic process GO:0009066 aspartate family amino acid metabolic process GO:0009068 aspartate family amino acid catabolic process GO:0015980 energy derivation by oxidation of organic compounds GO:0016054 organic acid catabolic process GO:0019474 L-lysine catabolic process to acetyl-CoA GO:0019477 L-lysine catabolic process GO:0033512 L-lysine catabolic process to acetyl-CoA via saccharopine GO:0035383 thioester metabolic process GO:0044282 small molecule catabolic process GO:0045333 cellular respiration GO:0046395 carboxylic acid catabolic process GO:0046440 L-lysine metabolic process GO:0046487 glyoxylate metabolic process GO:0051186 cofactor metabolic process GO:1901565 organonitrogen compound catabolic process GO:1901605 alpha-amino acid metabolic process GO:1901606 alpha-amino acid catabolic process
Molecular Function	GO:0004149 dihydrolipoyllysine-residue succinyltransferase activity GO:0016417 S-acyltransferase activity GO:0016746 transferase activity, transferring acyl groups GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups GO:0016748 succinyltransferase activity GO:0016751 S-succinyltransferase activity
Cellular Component	GO:0005759 mitochondrial matrix GO:0043209 myelin sheath GO:0045239 tricarboxylic acid cycle enzyme complex GO:0045240 dihydrolipoyl dehydrogenase complex GO:0045252 oxoglutarate dehydrogenase complex GO:1990204 oxidoreductase complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00020 Citrate cycle (TCA cycle) hsa00310 Lysine degradation hsa01100 Metabolic pathways hsa01200 Carbon metabolism
Reactome	R-HSA-71403: Citric acid cycle (TCA cycle) R-HSA-389661: Glyoxylate metabolism and glycine degradation R-HSA-6788656: Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism R-HSA-71064: Lysine catabolism R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-71406: Pyruvate metabolism and Citric Acid (TCA) cycle R-HSA-1428517: The citric acid (TCA) cycle and respiratory electron transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa00020 Citrate cycle (TCA cycle)
hsa00310 Lysine degradation
hsa01100 Metabolic pathways
hsa01200 Carbon metabolism

Reactome

R-HSA-71403: Citric acid cycle (TCA cycle)
R-HSA-389661: Glyoxylate metabolism and glycine degradation
R-HSA-6788656: Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism
R-HSA-71064: Lysine catabolism
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-71406: Pyruvate metabolism and Citric Acid (TCA) cycle
R-HSA-1428517: The citric acid (TCA) cycle and respiratory electron transport

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DLST and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DLST in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.35; FDR: 0.01650	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DLST in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.226	0.233
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.578	0.809
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.029	0.987
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.202	0.426
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.049	0.981
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.521	0.845
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.14	0.721
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.092	0.961
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.189	0.927
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.299	0.866
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.447	0.861
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.063	0.249

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DLST in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DLST. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DLST. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DLST. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DLST. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DLST expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DLST and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DLST
Name	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)
Aliases	DLTS; E2K; OGDC-E2; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; ......
Chromosomal Location	14q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DLST collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DLST